CN115400230B - 一种新型的多功能胃肠超声造影剂 - Google Patents
一种新型的多功能胃肠超声造影剂 Download PDFInfo
- Publication number
- CN115400230B CN115400230B CN202211075137.4A CN202211075137A CN115400230B CN 115400230 B CN115400230 B CN 115400230B CN 202211075137 A CN202211075137 A CN 202211075137A CN 115400230 B CN115400230 B CN 115400230B
- Authority
- CN
- China
- Prior art keywords
- contrast agent
- ultrasound contrast
- gastrointestinal
- echogenic
- microbubble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002496 gastric effect Effects 0.000 title claims abstract description 87
- 239000002961 echo contrast media Substances 0.000 title claims abstract description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 15
- 239000002872 contrast media Substances 0.000 claims abstract description 15
- 235000009566 rice Nutrition 0.000 claims abstract description 15
- 239000001814 pectin Substances 0.000 claims abstract description 14
- 229920001277 pectin Polymers 0.000 claims abstract description 14
- 235000010987 pectin Nutrition 0.000 claims abstract description 14
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 8
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 7
- 229940013618 stevioside Drugs 0.000 claims abstract description 7
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000725 suspension Substances 0.000 claims abstract description 5
- 241000209094 Oryza Species 0.000 claims description 14
- 238000007873 sieving Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 7
- 239000011812 mixed powder Substances 0.000 claims description 6
- 238000000643 oven drying Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000009736 wetting Methods 0.000 claims description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003632 minoxidil Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 241000792859 Enema Species 0.000 abstract description 6
- 239000007920 enema Substances 0.000 abstract description 6
- 229940095399 enema Drugs 0.000 abstract description 5
- 244000062793 Sorghum vulgare Species 0.000 abstract description 4
- 235000021307 Triticum Nutrition 0.000 abstract description 4
- 240000008042 Zea mays Species 0.000 abstract description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract description 4
- 235000005822 corn Nutrition 0.000 abstract description 4
- 235000019713 millet Nutrition 0.000 abstract description 4
- 108010011485 Aspartame Proteins 0.000 abstract description 3
- 244000068988 Glycine max Species 0.000 abstract description 3
- 235000010469 Glycine max Nutrition 0.000 abstract description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract description 3
- 235000010357 aspartame Nutrition 0.000 abstract description 3
- 239000000605 aspartame Substances 0.000 abstract description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 abstract description 3
- 229960003438 aspartame Drugs 0.000 abstract description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract description 3
- 230000000295 complement effect Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 235000013312 flour Nutrition 0.000 abstract description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract description 3
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 238000012285 ultrasound imaging Methods 0.000 abstract description 3
- 239000000230 xanthan gum Substances 0.000 abstract description 3
- 229920001285 xanthan gum Polymers 0.000 abstract description 3
- 235000010493 xanthan gum Nutrition 0.000 abstract description 3
- 229940082509 xanthan gum Drugs 0.000 abstract description 3
- 229920000084 Gum arabic Polymers 0.000 abstract description 2
- 239000000205 acacia gum Substances 0.000 abstract description 2
- 235000010489 acacia gum Nutrition 0.000 abstract description 2
- 229920000642 polymer Polymers 0.000 abstract description 2
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 244000098338 Triticum aestivum Species 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 description 12
- 238000002604 ultrasonography Methods 0.000 description 11
- 230000003902 lesion Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 230000002183 duodenal effect Effects 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 4
- 241000209140 Triticum Species 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 210000003384 transverse colon Anatomy 0.000 description 3
- 206010013554 Diverticulum Diseases 0.000 description 2
- 206010074061 Large intestinal stenosis Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000007667 floating Methods 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 208000024348 heart neoplasm Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000004482 other powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012713 Diaphragmatic hernia Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010023799 Large intestinal ulcer Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 201000000660 Pyloric Stenosis Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 201000005890 congenital diaphragmatic hernia Diseases 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010060865 duodenogastric reflux Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000009322 hypertrophic pyloric stenosis Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明公开一种新型的多功能胃肠超声造影剂,其特点为将由大米或小米或玉米或大豆或小麦或面粉,麦芽,陈皮,果胶或阿拉伯胶或黄原胶或羧甲基纤维素钠,甜菊糖苷或阿巴斯甜制成的有回声型胃肠超声对比剂30g用水配置成有回声型胃肠超声对比剂溶液700ml,加入微泡超声造影剂悬液,所述的微泡超声造影剂选自声诺维、示卓安、高分子微泡或其他微泡造影剂0.5‑3ml,搅匀后即可作为口服或灌肠造影使用。本发明联合应用有回声型胃肠超声对比剂与微泡超声造影剂,充分利用二者的优点,克服各自的不足,达到优势互补、协同增强超声显像的效果,具有较高的临床应用价值。
Description
技术领域
本发明属于医药和诊断技术领域,尤其涉及一种新型的多功能胃肠超声造影剂。
背景技术
胃肠内容物成分较为复杂,常含有较多量气体,而气体是干扰胃肠超声检查的最主要因素之一。当超声波在组织传播过程中遇到气体时,由于气体与软组织间界面的声阻抗差极大,99.9%的声能发生强反射,后方回声极度衰减形成声影,无法显示气体后方的组织结构。如何克服胃肠内容物,尤其是气体干扰,是提高胃肠超声检查效果的关键。
自20世纪70年代以来,国内外学者在胃肠超声显像剂的研制方面开展了大量的研究,温开水、汽水、5%碳酸氢钠溶液、中药口服液、有回声型胃肠超声显像剂等先后应用于胃肠超声检查。目前临床应用较多的为有回声型胃肠超声显像剂,其主要采用谷类食物,如大米、小米、玉米、小麦、芝麻等,或者加入一些理气健脾胃的药食两用中药,经熟化、粉碎、混匀制成,目前已有产品获准应用于临床。
有回声型胃肠超声显像剂在胃肠内存留时间较长,尤其适合观察胃肠壁低回声病灶,对十二指肠充盈效果明显优于无回声显像剂。特别重要的是,有回声显像剂可明显减少胃肠内气体产生的伪像的干扰,在很大程度提高了胃肠超声检查质量。但目前临床应用的有回声显像剂也存在一些不足:①加水调配比较困难,容易结坨,难以充分分散;②需要用沸水调配,等待冷却后才能使用,比较费时;③配制后的显像剂容易沉淀分层,导致图像回声不均匀;④显像剂剂在超声下呈中等偏低回声,与偏低回声病灶对比度欠佳,容易导致漏诊;⑤部分胃肠壁病灶,如息肉呈中等回声,有回声显像剂与病灶回声较接近,常难以辨别,容易漏诊;⑥部分患者由于胃肠肿瘤或炎症狭窄,进入病变区域的有回声型胃肠超声显像剂的量较少,使得超声检查灵敏度明显降低,容易漏诊或误诊;⑦部分患者由于肥胖等原因,超声检查回声衰减明显,严重影响有回声型胃肠超声显像剂的检查效果。
发明内容
本发明的目的是提供一种能协同增强超声显像效果的新型多功能胃肠超声造影剂。
本发明的目的是这样实现的,一种有回声型胃肠超声对比剂,其特征在于,由大米或小米或玉米或大豆或小麦或面粉,麦芽,陈皮,果胶或阿拉伯胶或黄原胶或羧甲基纤维素钠,甜菊糖苷或阿巴斯甜制成,上述各成分的质量百分比为70-75:12-18:7-12:1-3:0.01-0.3。
所述的有回声型胃肠超声对比剂,其特征在于,各成分的质量百分比为72.5:15:10:2.4:0.1。
本发明的目的是这样实现的,一种新型的多功能胃肠超声造影剂,其特征在于,将权利要求1或2所述的有回声型胃肠超声对比剂30g用水配置成有回声型胃肠超声对比剂溶液700ml,加入微泡超声造影剂悬液,所述的微泡超声造影剂选自声诺维、示卓安、高分子微泡或其他微泡造影剂0.5-3ml,搅匀后即可作为口服或灌肠造影使用。
与现有技术相比,本发明具有以下有益效果:本发明的新型多功能胃肠超声造影剂,联合应用有回声型胃肠超声对比剂与微泡超声造影剂,充分利用二者的优点,克服各自的不足,达到优势互补、协同增强超声显像的效果,具有较高的临床应用价值。
经过近两千临床病例验证,本发明的有回声型胃肠超声对比剂具有配制使用方便,性质稳定不分层,颗粒均匀一致,回声高亮,可明显减少超声伪像的干扰,对病灶检出率高达85%,具有较高的临床应用价值。然而,对于胃肠壁等回声病灶,有回声型胃肠超声对比剂与病灶回声较接近,病灶容易被对比剂“掩盖”,导致漏诊。另外,对于一些较困难的病例,如十二指肠降部病灶、消化道畸形或狭窄、肥胖患者等,有回声型胃肠超声对比剂的超声诊断敏感性仍比较低,常难以清晰显示病变。此时,联合应用有回声型胃肠超声对比剂与微泡超声造影剂制备成一种新型的多功能胃肠超声造影剂,可明显提高病灶的显示率,拓宽临床应用范围,提高临床诊断准确性与应用价值。
新型多功能胃肠超声造影剂秉承了有回声型胃肠超声对比剂与微泡超声造影剂的优点,优势互补,显示出协同增强造影效果:
(1)有回声型胃肠超声对比剂在胃肠内存留时间长,可提高胃肠超声造影检查的时间窗;
(2)有回声型胃肠超声对比剂可明显减少胃肠道气体干扰,减少超声伪像,提高超声图像质量;
(3)有回声型胃肠超声对比剂稳定性高,与微泡超声造影剂混合后,可使微泡造影剂均匀分布于溶液中,避免微泡由于浮力作用上浮而分层;
(4)微泡超声造影剂可显著增强背向散射信号,即使细小的病灶也能在超声造影下凸显出来,具有很高的诊断灵敏性和临床应用价值。
附图说明
图1为本发明的有回声型胃肠超声对比剂配制后实物拍照图。
图2为本发明的有回声型胃肠超声对比剂,将其注入新西兰兔胃内,呈均匀一致高回声超声检查图。
图3为口服有本发明的有回声型胃肠超声对比剂后,胃腔内呈高回声,发现贲门癌呈喇叭样增厚,病灶与对比剂“黑白分明”超声图。
图4为口服有本发明的口服有回声型胃肠超声对比剂后,清晰显示十二指肠降部低回声结节超声检查图。
图5为口服有本发明的新型多功能胃肠超声造影剂后,超声造影检查发现十二指肠降部憩室图。
图6为经肛门灌入本发明的新型多功能胃肠超声造影剂后,可清晰显示横结肠狭窄,局部可见溃疡龛影,深达浆膜层图。
具体实施方式
以下结合附图对本发明做进一步描述。
1)本发明的有回声型胃肠超声对比剂,配方成分为大米、麦芽、陈皮、果胶、甜菊糖苷,其最佳比例(质量百分比)为72.5:15:10:2.4:0.1。大米为主料,经充分研磨成小颗粒后,超声检查表现为较均匀一致的中高回声。配方中辅于药食两用中药,其中麦芽具有行气消食、健脾开胃的功效,陈皮具有理气健脾功效。果胶具有乳化稳定作用,可防止胃肠超声对比剂沉淀分层,还具有促进胃肠蠕动、润肠通便的功效。此外,甜菊糖苷可改善胃肠超声对比剂的口感,达到色香味俱全的效果。
本发明的有回声型胃肠超声对比剂的制备方法为:
(1)大米小火炒熟,至微黄色,研磨粉碎过100目筛;
(2)麦芽与陈皮置于烤箱,温度100℃,时间为1小时,烤干熟化后,研磨粉碎,过100目筛;
(3)将粉碎的大米、麦芽、陈皮,以及果胶、甜菊糖苷按质量百分比72.5:15:10:2.4:0.1比例充分混匀,得混合粉;
(4)每100g上述步骤(3)获得的混合粉中加入75ml 75wt%乙醇,调匀润湿,挤压过18目筛,制得湿颗粒;
(5)100℃烤箱烤干1小时,过10目及30目筛,其中过30目筛的小颗粒重复步骤(5)、(6),最终得到粒径大小较均一的颗粒剂;
(6)分装每包30g(可用700ml水配制),抽真空,密封。
将上述步骤1)制得的有回声型胃肠超声对比剂颗粒剂以每包30克加入温水700ml方式,配制成有回声型胃肠超声对比剂溶液,口服优选700ml,小儿可根据年龄酌减(200-600ml),灌肠优选1000 ml(2包共计60克,配制成1400ml,优选取1000 ml作为灌肠造影使用),根据患者年龄及耐受情况酌情增减(500-1400ml)。经过近两千临床病例验证,本发明的有回声型胃肠超声对比剂具有配制使用方便,性质稳定不分层,颗粒均匀一致,回声高亮,与病灶对比鲜明,可明显减少超声伪像的干扰,对病灶检出率高达85%以上,具有较高的临床应用价值。
可选地,大米可用其他谷物如小米、玉米、小麦、面粉、大豆等替代;
果胶可以采用其他的,如阿拉伯胶、黄原胶、羧甲基纤维素钠等替代;
甜菊糖苷可以采用阿巴斯甜等代替。
果胶在本发明中起到的作用主要是悬浮大米等颗粒,防止沉淀分层,这对于提高图像均匀一致性具有至关重要的作用。然而,果胶虽然能溶于水,但常规溶解方法需要加热搅拌较长时间才能溶解,费时费力,这无法应用于临床。本发明采用物理混合的方法将果胶粉与大米等粉末搅拌混匀,再通过乙醇湿润,烤干固定,制成颗粒剂,可使果胶粉充分分散于大米等粉末中,空间位阻作用可防止果胶粉粘连成坨。制成的颗粒剂在使用时倒入温水中,果胶即可充分溶解,极大提高了使用的方便性,便于产业化批量生产。
2)将上述步骤1)制得的有回声型胃肠超声对比剂以每包30克,加入温水700ml方式,配制成有回声型胃肠超声对比剂溶液。每700ml有回声型胃肠超声对比剂加入微泡超声造影剂悬液0.5-3ml,优选1ml,搅匀后即为新型多功能胃肠超声造影剂,可作为口服或灌肠使用。上述的微泡超声造影剂可以选用声诺维、示卓安,或其他高分子、磷脂等微泡超声造影剂。新型多功能胃肠超声造影剂口服优选700ml,小儿可根据年龄身高酌减(200-600ml);灌肠优选1000 ml(2包共计60克,配制1400ml,优选取1000 ml作为灌肠造影使用),根据患者年龄身高及耐受情况酌情增减(500-1400ml)。经过500多病例临床验证,其对病灶的检出率高达95%,具有极高的临床应用价值。
本发明的新型多功能胃肠超声造影剂的适应证:
(1)胃肠壁占位性病变,如胃肠癌、胃肠间质瘤、平滑肌瘤、息肉、淋巴瘤、神经内分泌肿瘤、脂肪瘤等;
(2)胃肠炎性疾病,如消化性溃疡、炎症性肠病、坏死性小肠结肠炎等;
(3)胃肠动力障碍性疾病,如功能性消化不良、胃瘫、胃食管返流病、十二指肠胃反流等;
(4)胃肠先天异常,如胃肠重复畸形、膈疝、先天性肥厚性幽门狭窄、异位胰腺等;
(5)其他,如胃肠异物、胃下垂、胃巨黏膜皱襞症、胃底静脉曲张等。
本发明的新型多功能胃肠超声造影剂的禁忌证:
当患者患有急性胰腺炎、胃肠穿孔、胃肠梗阻、胃肠扭转、急性胃扩张等疾病,临床上禁食禁水时,不能饮水或口服胃肠超声显像剂,但可以做普通的腹部超声检查。
实施例一:
本发明的上述步骤1)制得的有回声型胃肠超声对比剂,每包30克,缓缓倒入700ml温水中,充分搅拌均匀,即可使用,色香味俱全(见图1),将其注入新西兰兔胃内,呈均匀一致高回声(图2)。
实施例二:
老年男性,吞咽困难就诊,口服有回声型胃肠超声对比剂700ml(制备方法同实施例一)后,胃腔内呈高回声,发现贲门癌呈喇叭样增厚的低回声,病灶与对比剂“黑白分明”(图3)。
实施例三:
老年女性患者,上腹部不适就诊,常规超声检查未发现明显异常,口服有回声型胃肠超声对比剂700ml(制备方法同实施例一)后,清晰显示十二指肠降部低回声结节(图4)。图中箭头所示为十二指肠结节。
实施例四:
老年女性患者,反复上腹部绞痛就诊,常规超声检查未发现明显异常,口服多功能胃肠超声造影剂700ml(制备方法同实施例一)后,超声造影检查发现十二指肠降部憩室(图5)。图中箭头所示为十二指肠降部,三角号所示为憩室。
实施例五:
中年男性患者,反复腹痛腹泻30年,常规超声检查腹部未见明显异常,经肛门灌入新型多功能胃肠超声造影剂1000ml(制备方法同步骤2)后,可清晰显示横结肠狭窄,局部可见溃疡龛影,深达浆膜层(图6)。图中箭头所示为横结肠溃疡灶(龛影)。
以上结合具体的实施方式对本申请进行了描述,但本领域技术人员应该清楚,这些描述都是示例性的,并不是对本申请保护范围的限制。本领域技术人员可以根据本申请的精神和原理对本申请做出各种变型和修改,这些变型和修改也在本申请的范围内。
Claims (2)
1.一种多功能胃肠超声造影剂,其特征在于,将有回声型胃肠超声对比剂30g用水配置成有回声型胃肠超声对比剂溶液700ml,加入微泡超声造影剂悬液0.5-3ml搅匀后即可;
所述有回声型胃肠超声对比剂的制备方法为:
(1)大米小火炒熟,至微黄色,研磨粉碎过100目筛;
(2)麦芽与陈皮置于烤箱,温度100℃,时间为1小时,烤干熟化后,研磨粉碎,过100目筛;
(3)将粉碎的大米、麦芽、陈皮,以及果胶、甜菊糖苷按质量百分比72.5∶15∶10∶2.4∶0.1比例充分混匀,得混合粉;
(4)每100g上述步骤(3)获得的混合粉中加入75ml 75wt%乙醇,调匀润湿,挤压过18目筛,制得湿颗粒;
(5)100℃烤箱烤干1小时,过10目及30目筛,其中过30目筛的小颗粒重复步骤(5),最终得到粒径大小较均一的颗粒剂;
所述的微泡超声造影剂选自声诺维、示卓安。
2.一种多功能胃肠超声造影剂,其特征在于,将有回声型胃肠超声对比剂30g用水配置成有回声型胃肠超声对比剂溶液700ml,加入微泡超声造影剂悬液0.5-3ml搅匀后即可;
所述有回声型胃肠超声对比剂的制备方法为:
(1)大米小火炒熟,至微黄色,研磨粉碎过100目筛;
(2)麦芽与陈皮置于烤箱,温度100℃,时间为1小时,烤干熟化后,研磨粉碎,过100目筛;
(3)将粉碎的大米、麦芽、陈皮,以及果胶、甜菊糖苷按质量百分比72.5∶15∶10∶2.4∶0.1比例充分混匀,得混合粉;
(4)每100g上述步骤(3)获得的混合粉中加入75ml 75wt%乙醇,调匀润湿,挤压过18目筛,制得湿颗粒;
(5)100℃烤箱烤干1小时,过10目及30目筛,其中过30目筛的小颗粒重复步骤(5),最终得到粒径大小较均一的颗粒剂;
所述的微泡超声造影剂选自高分子微泡造影剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211075137.4A CN115400230B (zh) | 2022-09-03 | 2022-09-03 | 一种新型的多功能胃肠超声造影剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211075137.4A CN115400230B (zh) | 2022-09-03 | 2022-09-03 | 一种新型的多功能胃肠超声造影剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115400230A CN115400230A (zh) | 2022-11-29 |
CN115400230B true CN115400230B (zh) | 2023-12-22 |
Family
ID=84164324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211075137.4A Active CN115400230B (zh) | 2022-09-03 | 2022-09-03 | 一种新型的多功能胃肠超声造影剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115400230B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117838893B (zh) * | 2024-03-07 | 2024-05-14 | 延边峻屹医疗科技有限公司 | 一种混悬凝胶剂及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1030186A (zh) * | 1988-04-26 | 1989-01-11 | 郭心璋 | 超声显象剂及其制法 |
CN1056634A (zh) * | 1990-05-18 | 1991-12-04 | 辛苔蒂加股份有限公司 | 超声回波记录仪用液载悬浮体之充气聚合物微气球 |
US5107842A (en) * | 1991-02-22 | 1992-04-28 | Molecular Biosystems, Inc. | Method of ultrasound imaging of the gastrointestinal tract |
CN108939097A (zh) * | 2018-09-13 | 2018-12-07 | 中国医科大学附属盛京医院 | 一种即用液态型口服胃超声显影剂配方及制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2956945T3 (es) * | 2017-02-28 | 2024-01-05 | Lument Ab | Polvo para agente de contraste negativo oral |
-
2022
- 2022-09-03 CN CN202211075137.4A patent/CN115400230B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1030186A (zh) * | 1988-04-26 | 1989-01-11 | 郭心璋 | 超声显象剂及其制法 |
CN1056634A (zh) * | 1990-05-18 | 1991-12-04 | 辛苔蒂加股份有限公司 | 超声回波记录仪用液载悬浮体之充气聚合物微气球 |
US5107842A (en) * | 1991-02-22 | 1992-04-28 | Molecular Biosystems, Inc. | Method of ultrasound imaging of the gastrointestinal tract |
CN108939097A (zh) * | 2018-09-13 | 2018-12-07 | 中国医科大学附属盛京医院 | 一种即用液态型口服胃超声显影剂配方及制备方法 |
Non-Patent Citations (1)
Title |
---|
杨丽珍等.《常用中药中西医结合临床应用手册》.江西科学技术出版社,1998,(第1版),第356页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115400230A (zh) | 2022-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115400230B (zh) | 一种新型的多功能胃肠超声造影剂 | |
CN1686308A (zh) | 一种治疗胃炎和胃溃疡的药物及其制备方法 | |
Sullivan et al. | Gastric disease in the dog and cat | |
CN105079829B (zh) | 一种口服高回声腹部胃肠道超声检查助显剂及其制备方法 | |
Hamidi et al. | A rare clinic entity: Huge trichobezoar | |
Iyer et al. | Imaging of pediatric desmoplastic small–round-cell tumor with pathologic correlation | |
Li et al. | Surgery combined with molecular targeted therapy successfully treated giant esophageal gastrointestinal stromal tumor | |
CN1403160A (zh) | 胃肠彩色超声造影剂 | |
Scafidi et al. | Diffuse neonatal gastrointestinal hemangiomatosis: CT findings | |
Mathur et al. | Gastric teratoma in children: our experience | |
CN110755646A (zh) | 一种用于胃部超声造影检查的中药造影助显剂及其制备方法 | |
Surov et al. | Ectopic pancreas with pseudocyst and pseudoaneurysm formation | |
Thanh et al. | Extragastrointestinal stromal tumor presenting as an exophytic prostatic mass | |
Belágyi et al. | Multiorgan resection (including the pancreas) for metastasis of cutaneous malignant melanoma | |
전소언 et al. | Metastasis of Breast Cancer Presenting as Enlarged Folds in the Stomach | |
CN108472323B (zh) | 包含藻蛋白多糖提取物的组合物及其用途 | |
CN117563021A (zh) | 一种超声造影剂 | |
Rice et al. | Computed tomography and ultrasonography of carcinoma in duplication cysts | |
Chan et al. | Uterine lipoleiomyoma: ultrasound and computed tomography findings | |
Liu et al. | Breast mass due to alveolar soft part sarcoma of the pectoris major muscle | |
CN107510754A (zh) | 一种治疗癌症中药 | |
Jothilakshmi et al. | Symptomatic hepatic hemangioendothelioma in a newborn | |
Salles et al. | Megastomach caused by a pyloric schwannoma in a young woman | |
Gonzalez et al. | 2640 Intractable Celiac Disease in IgA Deficiency | |
Heis et al. | S2288 Primary Signet Cell Carcinoma of the Ileum: A Rare Differential Diagnosis of Acute Abdominal Pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |